Last Updated on October 10, 2024 by The Health Master
IPC
The Indian Pharmacopoeia Commission (IPC), a leading drug standards body in India, has issued a crucial drug safety alert regarding two commonly prescribed medicines: amlodipine and acetazolamide.
This alert highlights potential adverse reactions associated with these drugs, urging healthcare professionals and patients to exercise caution.
Amlodipine: Potential for Lichenoid Keratosis
Amlodipine, widely used for managing heart conditions like coronary heart disease, myocardial infarction (heart attack), and preventing stroke, may cause lichenoid keratosis.
This is an inflammatory skin condition characterized by rough, scaly patches that typically appear on the forearms, hands, chest (particularly in middle-aged women), or sun-exposed areas.
Key Points about Amlodipine:
- Treats and prevents various heart ailments.
- May cause lichenoid keratosis, a skin inflammation.
- Lesions commonly appear on forearms, hands, chest, and sun-exposed areas.
Acetazolamide: Risk of Choroidal Effusion/Detachment
Acetazolamide, a carbonic anhydrase inhibitor, is a medicine commonly used to treat glaucoma.
However, the IPC alert suggests a potential link to choroidal effusion or detachment.
This condition involves fluid buildup within the choroid layer of the eye, which can impact vision.
Key Points about Acetazolamide:
- Used for treating glaucoma, a condition affecting eye pressure.
- May lead to choroidal effusion or detachment, causing fluid buildup in the eye.
Recommendations for Healthcare Professionals and Patients
- Healthcare Professionals: The IPC advises healthcare providers to diligently monitor patients for potential adverse drug reactions (ADRs) while administering amlodipine and acetazolamide.
- Patients: Individuals taking these medicines are encouraged to closely monitor themselves for any signs of the mentioned ADRs.
Potential Packaging Updates and Ongoing Monitoring
The IPC alert may lead to stricter regulations.
Pharmaceutical companies manufacturing these drugs might be required to include warnings within the packaging, clearly informing patients and doctors about the potential adverse events.
Basis of the IPC Warning
The IPC warning is based on a preliminary analysis of data collected through the Pharmacovigilance Programme of India (PvPI) database. This program continuously monitors and reports on ADRs associated with various medicines.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
Indian Pharmacopoeia Commission releases Addendum 2024 to IP 2022
Latest on Indian Pharmacopoeia Commission (IPC)
Latest Circulars: (IPC) Indian Pharmacopoeia Commission
Latest Notifications regarding Pharmaceuticals
Latest on National Formulary of India (NFI)
High Court: Expedite framing policy for online sale of drugs
Telangana DCA: Counterfeit Drugs Worth Rs. 23 Lakhs seized
CDSCO: Guidance document on Export NOC for Pharma Industry
Mounjaro Gets Green Light from Expert Committee for Weight Management
Chemists seek clarification on substitution of branded medicines with generics
USFDA Tentative Approval granted for Bosutinib Tablets
Govt Launches new Portal to Protect Children from Drug Abuse in India
Fake Medicine Racket Busted in Nagpur: One Arrest
531 Pharmaceutical Stores, Outlets sealed in Nigeria
Gujarat FDCA busted illegal medicine operation
DCGI announces Stringent Measures and Digital Transformation Plans
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
